At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 313 enrolled
Drug / intervention
M1095 (Sonelokimab) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
In Brief
A Phase 2 clinical trial evaluating M1095 (Sonelokimab), Placebo, and 1 other intervention for Psoriasis. Completed, enrolled 313 participants across 60 sites in 7 countries.
Detailed Summary
This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesBulgaria, Canada, Czechia, Germany, Hungary, Poland, United States
CollaboratorsAvillion LLP
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJul 2018
Primary CompletionJun 2019
Study CompletionMar 2020
TodayJul 2026
First PostedDec 27, 2017
Enrollment StartJul 31, 2018
Primary CompletionJun 20, 2019
Study CompletionMar 26, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.5 years ago
Interventions
M1095 (Sonelokimab)drug
M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
Placebodrug
Placebo contains no active drug.
Secukinumabdrug
Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.